Drug Trial Radar · NCT07668180
A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia
Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- HK inno.N CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.
Conditions
- Sarcopenia in Elderly
Interventions
IN-207907 120 mgDrug
IN-207907 120 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
IN-207907 240 mgDrug
IN-207907 240 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
IN-207907 360 mgDrug
IN-207907 360 mg will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
PlaceboDrug
Placebo will be administered by intravenous injection at 4-week intervals for a total of 3 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Short Physical Performance Battery (SPPB) total scoreTime frame: From baseline to week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.